Page last updated: 2024-09-05

dofequidar and fluorouracil

dofequidar has been researched along with fluorouracil in 1 studies

Compound Research Comparison

Studies
(dofequidar)
Trials
(dofequidar)
Recent Studies (post-2010)
(dofequidar)
Studies
(fluorouracil)
Trials
(fluorouracil)
Recent Studies (post-2010) (fluorouracil)
402545,5629,30714,663

Protein Interaction Comparison

ProteinTaxonomydofequidar (IC50)fluorouracil (IC50)
Epidermal growth factor receptorHomo sapiens (human)0.32
Thymidylate synthaseMus musculus (house mouse)1.58
AromataseHomo sapiens (human)0.63

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aogi, K; Asaga, T; Ikeda, T; Ito, Y; Kobayashi, T; Minami, H; Noguchi, S; Nomizu, T; Ohashi, Y; Saeki, T; Sato, W; Toi, M; Tsuruo, T; Yamamoto, N1

Trials

1 trial(s) available for dofequidar and fluorouracil

ArticleYear
Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Feb-01, Volume: 25, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Double-Blind Method; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Quinolines; Treatment Outcome

2007